Perspective Therapeutics (CATX) Non-Current Deffered Revenue (2024 - 2026)

Perspective Therapeutics has disclosed Non-Current Deffered Revenue across 3 years of filings, most recently posting $26.6 million for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $26.6 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.6 million (changed 0.0% YoY), and the FY2025 annual result was $26.6 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue came in at $26.6 million for Q1 2026 at Perspective Therapeutics, roughly flat from $26.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $26.6 million in Q1 2024 to a low of $26.6 million in Q1 2024.
• The 3-year median for Non-Current Deffered Revenue is $26.6 million (2024), against an average of $26.6 million.
• Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
• Perspective Therapeutics' Non-Current Deffered Revenue stood at $26.6 million in 2024, then changed by 0.0% to $26.6 million in 2025, then changed by 0.0% to $26.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $26.6 million (Q1 2026), $26.6 million (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.